HCV genomic sequences for diagnostics and therapeutics
AssigneeChiron Corporation
InventorsTai-An Cha, Eileen Beall, Bruce Irvine, Janice Kolberg, Michael S. Urdea
Life of this patent
Estimating the term…
Abstract
The present application features nucleic acid, peptide and antibody compositions relating to genotypes of hepatitis C virus and methods of using such compositions for diagnostic and therapeutic purposes.
Claims11
A non-naturally occurring nucleic acid comprising a necleotide sequence of about 15 or more nucleotides wherein at least fifteen contiguous nucleotides are fully homologous or fully complementary to a nucleotide sequence within a hepatitis C viral genome, wherein said nucleotide sequence is selected from or within a sequence selected from the group consisting of SEQ ID NOs:
- 24-32, provided that said nucleotide sequence is within a hepatitis C viral genome which is not HCV-1, HCV-J1, HCV-J4, or HCV-J7, and wherein the nucleic acid is no longer than about 100 nucleotides.
A non-naturally occurring nucleic acid comprising a nucleotide sequence of about 24 or more nucleotides wherein at least twenty-four contiguous nucleotides are fully homologous or fully complementary to a nucleotide sequence within a hepatitis C viral genome, wherein said nucleotide sequence is selected from or within a sequence selected from the group consisting of SEQ ID NOs:
- 24-32, provided that said nucleotide sequence is within a hepatitis C viral genome which is not HCV-1, HCV-J1, HCV-J4, or HCV-J7, and wherein the nucleic acid is no longer than about 100 nucleonides.
A non-naturally occurring nucleic acid comprising a nucleotide sequence of about 24 or more nucleotides wherein at least fifteen contiguous nucelotides are fully homologous or fully complementary to a nucleotide sequence within a hepaitis C viral genome, wherein said nucleotide sequence is selected from the group consisting of or within a sequence selected from SEQ ID NOs:
- 35, 36, 38-45, 48, and 49, provided that said nucleotide sequence is within a hepatitis C viral genome which is not HCV-1, HCV-J1, HCV-J4, HCV-J7, and wherein the nucleic acid is no longer than about 252 nucleotides.
A non-naturally occurring nucleic acid comprising a nucleotide seqence of about 24 or more nucleotides wherein at least fifteen contiguous nucleotides are fully homologous or fully complementary to a nucleotide sequence with a hepatitis C viral genome, wherein said nucleotide sequence is selected from the group consisting of or within a sequence selected from SEQ ID NOs:
- 50 and 51, provided that said nucleotide sequence is within a hepatitis C viral genorme which is not HCV-1, HCV-J1, HCV-J4, HCV-J37, and wherein the nucleic acid is no longer than about 180 nucleotides.
A non-naturally occurring nucleic acid comprising a nucleotide sequence of about 24 or more nucleotides wherein at least twenty-four contiguous nucleotides are fully homologous or fully complementary to a nucleotide sequence within a hepatitis C viral genome, wherein said nucleotide sequence is selected from the group consisting of or within a sequence selected from SEQ ID NOs:
- 35, 36, 38-45, 48, and 49, provided that said nuclcotide sequence is within a hepatitis C viral genome which is not HCV-1, HCV-J1, HCV-J4, HCV-J7, and wherein the nucleic acid is no longer thin about 252 nucleotides.
A non-naturally occurring nucleic acid comprising a nucleotide sequence of about 24 or more nucleotides wherein at least twenty-four contiguous nucleotides are fully homologous or fully complementsy to a nucleotide sequence within a hepatitis C viral genome, wherein said nucleotide sequence is selected from the group consisting of or within a sequence selected from SEQ ID NOs:
- 50 and 51, provided that said nucleotide sequence is within a hepatitis C viral genome which is not HCV-1, HCV-J1, HCV-J4, HCV-J7, and wherein the nucleic acid is no longer than about 180 nucleotides.
Dependencies are inferred from the claim text.